BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Duloxetine

A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.

993+ PubMed studies analyzed · 369 RCTs · Evidence Score: 73

Research Domains

Duloxetine has been studied across 17 research domains including 🌤️ Mood & Depression, 💊 Pain, 🧘 Stress & Anxiety, 😴 Sleep, 🦴 Bone & Joint. The primary research focus is 🌤️ Mood & Depression with 51% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Duloxetine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Cabergoline
15 shared targets
prochlorperazine
15 shared targets
fananserin
13 shared targets
thioridazine
16 shared targets
clemastine
14 shared targets
ritanserin
14 shared targets
clomipramine
13 shared targets
Benzethonium
16 shared targets
brexpiprazole
14 shared targets
ziprasidone
11 shared targets
Loading evidence profile...

This evidence profile for Duloxetine is generated deterministically from 993 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.